Sugi Predict

Sugi Predict / Compounds / SCHEMBL4596077

SCHEMBL4596077

SCHEMBL4596077

COc1cccc(C[C@@H](N)C(=O)O)c1

nearest known ligand 0.66

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 2/20 0.66
▸ SLC7A5 Q01650 6/20 0.65
▸ ALPI P09923 1/20 0.59
▸ PKM P14618 1/20 0.59
▸ PTGS1 P23219 1/20 0.59
▸ XIAP P98170 1/20 0.59
▸ NOS3 P29474 2/20 0.58
▸ NOS1 P29475 2/20 0.58
▸ NOS2 P35228 2/20 0.58
▸ GRIA2 P42262 1/20 0.56
▸ CYP1A2 P05177 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL146611 1.00 TAAR1 (0.66) TAAR1SLC7A5ALPIPKMPTGS1
SCHEMBL29855157 1.00 TAAR1 (0.66) TAAR1SLC7A5ALPIPKMPTGS1
SCHEMBL146610 1.00 TAAR1 (0.66) TAAR1SLC7A5ALPIPKMPTGS1
Acetic Acid SCHEMBL8720061 0.98 TAAR1 (0.64) TAAR1SLC7A5ALPIPKMPTGS1
SCHEMBL31369825 0.91 GRIA2 (0.66) TAAR1SLC7A5ALPIPKMPTGS1
SCHEMBL19943588 0.89 TAAR1 (0.68) TAAR1SLC7A5CYP1A2
SCHEMBL19766433 0.86 SLC7A5 (0.59) TAAR1SLC7A5ALPIPKMPTGS1
SCHEMBL1279049 0.86 TAAR1 (0.64) TAAR1SLC7A5
SCHEMBL3156480 0.86 SLC7A5 (0.59) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL22458056 0.86 TAAR1 (0.64) TAAR1SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025100520-A1 PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE ペプチドリーム株式会社 2025-05-15 — — WO claimed
US-20260049060-A1 TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS NATIONAL HEALTH RES INST (TW) 2026-02-19 — — US disclosed
WO-2025100520-A1 PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE ペプチドリーム株式会社 2025-05-15 — — WO disclosed
CN-109790114-B Novel chiral ligand, metal chelate, various unnatural amino acids and synthesis method of maraviroc and key intermediate thereof 中国科学院上海药物研究所 2025-03-07 — — CN disclosed
US-20230040236-A1 Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications PALATIN TECHNOLOGIES, INC. (US) 2023-02-09 — — US disclosed
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2023-01-05 — — US disclosed
CN-115515617-A Diamine-linked receptor-specific cyclic peptides 帕拉丁科技公司 2022-12-23 — — CN disclosed
EP-4100040-A1 DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES Palatin Technologies, Inc. (US) 2022-12-14 — — EP disclosed
US-20220002280-A1 COMPOUNDS AND METHODS OF USE FERRO THERAPEUTICS INC (US) 2022-01-06 — — US disclosed
US-11066416-B2 Rapafucin derivative compounds and methods of use thereof THE JOHNS HOPKINS UNIVERSITY (US) 2021-07-20 — — US disclosed
US-11040964-B2 Compounds and methods of use Ferro Therapeutics, Inc. (US) 2021-06-22 — — US disclosed
US-20210094933-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2021-04-01 — — US disclosed
US-20200299283-A1 COMPOUNDS AND METHODS OF USE BRIDGEBIO PHARMA, INC. 2020-09-24 — — US disclosed
US-20200040004-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RAPAFUSYN PHARMACEUTICALS, INC. 2020-02-06 — — US disclosed
US-20080318947-A1 Inhibitors of Akt Activity HEERDING DIRK A 2008-12-25 — — US disclosed
EP-1874768-A2 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2008-01-09 — — EP disclosed
WO-2006113837-A2 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2006-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049060-A1 TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS OPRK1, OPRD1, OPRM1 TAAR1 8/4885SLC7A5 2400/4885ALPI 3775/4885
US-11066416-B2 Rapafucin derivative compounds and methods of use thereof RICTOR, FKBP14, MTOR TAAR1 4860/4885SLC7A5 2832/4885ALPI 4284/4885
US-20200040004-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR TAAR1 4860/4885SLC7A5 2832/4885ALPI 4284/4885
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR TAAR1 4860/4885SLC7A5 2832/4885ALPI 4284/4885
US-20210094933-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR TAAR1 4860/4885SLC7A5 2832/4885ALPI 4284/4885
US-20220002280-A1 COMPOUNDS AND METHODS OF USE AIFM2, GPX4, GPX1 TAAR1 4158/4885SLC7A5 1000/4885ALPI 4308/4885
US-20200299283-A1 COMPOUNDS AND METHODS OF USE AIFM2, GPX4, GPX1 TAAR1 4158/4885SLC7A5 1000/4885ALPI 4308/4885
US-11040964-B2 Compounds and methods of use AIFM2, GPX4, GPX1 TAAR1 4158/4885SLC7A5 1000/4885ALPI 4308/4885
US-20080318947-A1 Inhibitors of Akt Activity PI4KB, PIK3CA, AKT2 TAAR1 4680/4885SLC7A5 3849/4885ALPI 1828/4885
US-20230040236-A1 Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications MC1R, MC3R, MC5R TAAR1 107/4885SLC7A5 754/4885ALPI 994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.